Share price movements do not necessarily reflect the business performance, but (a) 1H revenue performance expected to be very different from previous years is of concern, and (b) trump presidency and the quite dramatic changes that keep on popping up would be cause for concern for the pharma industry as a whole
On the positive side:
- the Australia business is profitable and hopefully that expanded scope of practice and full scope of practice will start to gain traction and revenues from that drop to the bottom line
- the US pharma industry is a beast.......I'm sure they are trying to work out how best to navigate the vaccine sceptics to burn the industry down, but the US market for these companies has not got to be their biggest profit centre on the planet by accident.......they have a huge vested interest in Americans taking drugs and at inflated prices, so they are going to use all their influence to maintain the status quo and with medadvisor tapping in directly to consumers, you would think they might get some of that marketing budget (again who knows with the trump & the nutters around him).
Add to My Watchlist
What is My Watchlist?
